TiumBio Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Huntaek Kim

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	31.5%
Management average tenure	no data
Board average tenure	no data

Recent management updates

No updates

Recent updates

We Think TiumBio (KOSDAQ:321550) Has A Fair Chunk Of Debt

Jun 20

CEO

Huntaek Kim (58 yo)

no data

Tenure

Mr. Hun-Taek Kim serves as Chief Executive Officer of TiumBio Co. Ltd. He received his Bachelor's degree from College of Veterinary Medicine, Seoul National University, Master's degree from College of Vete...

TiumBio Management

Management criteria checks 0/4

Key information

Recent management updates

Recent updates

New minor risk - Share price stability

New minor risk - Market cap size

TiumBio Co., Ltd. Announces First Patient Dosed in Phase 2 Clinical Trial of Oral Immuno-Oncology Drug TU2218

TiumBio Co., Ltd. Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024

We Think TiumBio (KOSDAQ:321550) Has A Fair Chunk Of Debt

Tiumbio Co., Ltd. Presents Phase 1B Interim Results for Tu2218 in Combination with Pembrolizumab At Asco 2024 Annual Meeting

TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain

Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

TiumBio Co., Ltd. Announces to Initiate Phase 2 Trial of TU2218 for Cancer

New minor risk - Revenue size

New minor risk - Shareholder dilution

TiumBio Co., Ltd. announced that it has received KRW 49.99982815 billion in funding

TiumBio Co., Ltd. announced that it has received KRW 25 billion in funding

New 90-day low: ₩16,000

New 90-day high: ₩18,000

New 90-day high: ₩18,900

New 90-day high - ₩17,950

CEO

Tenure